Fennec Pharmaceuticals (FRX) Price & Analysis

Compare

27 Followers

FRX Stock Chart & Stats

C$11.25

C$0.03(0.34%)

At close: Jan 08 4:00 PM EST

C$11.25

C$0.03(0.34%)

Day’s Range― - ―

52-Week RangeC$7.02 - C$13.83

Previous CloseN/A

Volume1.30K

Average Volume (3M)790.00

Market Cap

C$361.88M

Enterprise ValueC$356.93M

Total Cash (Recent Filing)C$21.93M

Total Debt (Recent Filing)C$18.09M

Price to Earnings (P/E)―

Beta1.85

Next Earnings

Apr 01, 2026

EPS Estimate

0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding34,139,973

10 Day Avg. Volume143

30 Day Avg. Volume790

Financial Highlights & Ratios

PEG Ratio3.19

Price to Book (P/B)-22.88

Price to Sales (P/S)2.83

P/FCF Ratio4.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$17.91

Price Target Upside59.24% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.2

Revenue Forecast (FY)C$63.11M

Bulls Say, Bears Say

Bulls Say

Guideline EndorsementsPEDMARK is recommended for the adolescent and young adult (AYA) population by the National Comprehensive Cancer Network (NCCN) with a 2A endorsement.

International ExpansionEuropean and international advancement continuing with the acceptance of PEDMARQSI® by the Scottish Medicines Consortium (SMC) for use in Scotland.

Product AdoptionA large national oncology group has added PEDMARK to its formulary for patients under 40 years of age, signaling momentum for broader adoption in community settings.

Bears Say

Fennec Pharmaceuticals News

Fennec announces planned initiation of IST by City of Hope to evaluate PEDMARK

Fennec (FENC) Pharmaceuticals announced the planned initiation of an investigator-sponsored study, IST, by City of Hope, a U.S....

6d ago

FENC

Fennec announces Phase 2/3 STS-J01 trial met primary endpoint

Fennec (FENC) Pharmaceuticals announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK for...

13d ago

FENC

Fennec completes full debt redemption

Fennec (FENC) Pharmaceuticals has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor Opportunities Fund...

26d ago

FENC

Fennec Pharmaceuticals Supports New Trial for Hearing Loss Prevention in Cancer Treatment

Fennec Pharmaceuticals ( ($TSE:FRX) ) has shared an announcement. Fennec Pharmaceuticals announced an investigator-sponsored trial by City of...

6d ago

FENC

Fennec Pharmaceuticals Reports Positive Results for PEDMARK® in Japan

The latest announcement is out from Fennec Pharmaceuticals ( ($TSE:FRX) ). Fennec Pharmaceuticals announced positive results from a...

13d ago

FENC

Fennec Pharmaceuticals Completes Full Debt Redemption, Strengthening Financial Position

Fennec Pharmaceuticals ( ($TSE:FRX) ) has issued an update. Fennec Pharmaceuticals has successfully completed the full redemption of...

26d ago

FENC

Fennec Pharmaceuticals Closes $5M Private Offering in Canada

Fennec Pharmaceuticals ( ($TSE:FRX) ) just unveiled an update. Fennec Pharmaceuticals announced the successful closing of a non-brokered...

27d ago

FENC

Fennec Pharmaceuticals Reports Increased PEDMARK Sales

Fennec Pharmaceuticals ( ($FENC) ) has released its Q3 earnings. Here is a breakdown of the information Fennec...

28d ago

FENC

Fennec Pharmaceuticals Announces Underwriting Agreement for Share Offering

Fennec Pharmaceuticals ( ($TSE:FRX) ) has issued an announcement. On November 13, 2025, Fennec Pharmaceuticals announced an underwriting...

28d ago

FENC

Fennec 4.7M share Spot Secondary priced at $7.50

Piper Sandler and Craig-Hallum acted as joint book running managers for the offering. Published first on TheFly –...

1M ago

FENC

Fennec Pharmaceuticals Prices Public Offering to Raise $35 Million

Fennec Pharmaceuticals ( ($TSE:FRX) ) just unveiled an update. Fennec Pharmaceuticals announced the pricing of its public offering...

1M ago

FENC

Fennec Pharmaceuticals Announces Private Offering to Bolster Financial Position

Fennec Pharmaceuticals ( ($TSE:FRX) ) has issued an announcement. Fennec Pharmaceuticals announced a non-brokered private offering of its...

1M ago

FENC

Fennec Pharmaceuticals Achieves Record Sales and Profitability in Q3 2025

Fennec Pharmaceuticals ( ($TSE:FRX) ) just unveiled an update. Fennec Pharmaceuticals reported a record-breaking third quarter in 2025,...

1M ago

FENC

Fennec Pharmaceuticals Announces Public Offering to Bolster Financial Strategy

Fennec Pharmaceuticals ( ($TSE:FRX) ) just unveiled an announcement. Fennec Pharmaceuticals announced a proposed public offering of its...

1M ago

FENC

FRX FAQ

What was Fennec Pharmaceuticals’s price range in the past 12 months?

Fennec Pharmaceuticals lowest stock price was C$7.02 and its highest was C$13.83 in the past 12 months.

What is Fennec Pharmaceuticals’s market cap?

Fennec Pharmaceuticals’s market cap is C$361.88M.

When is Fennec Pharmaceuticals’s upcoming earnings report date?

Fennec Pharmaceuticals’s upcoming earnings report date is Apr 01, 2026 which is in 107 days.

How were Fennec Pharmaceuticals’s earnings last quarter?

Fennec Pharmaceuticals released its earnings results on Nov 13, 2025. The company reported -C$0.028 earnings per share for the quarter, beating the consensus estimate of -C$0.031 by C$0.003.

Is Fennec Pharmaceuticals overvalued?

According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fennec Pharmaceuticals pay dividends?

Fennec Pharmaceuticals does not currently pay dividends.

What is Fennec Pharmaceuticals’s EPS estimate?

Fennec Pharmaceuticals’s EPS estimate is 0.05.

How many shares outstanding does Fennec Pharmaceuticals have?

Fennec Pharmaceuticals has 34,139,973 shares outstanding.

What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?

Fennec Pharmaceuticals reported an EPS of -C$0.028 in its last earnings report, beating expectations of -C$0.031. Following the earnings report the stock price went down -1.109%.

Which hedge fund is a major shareholder of Fennec Pharmaceuticals?

Currently, no hedge funds are holding shares in TSE:FRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Fennec Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-16.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. (FRX) is a biopharmaceutical company focused on the development and commercialization of innovative cancer treatments. The company operates primarily in the biotechnology sector and is dedicated to addressing the critical needs of cancer patients, particularly in the area of pediatric oncology. Its flagship product, PEDMARK, is designed to prevent ototoxicity, which is hearing loss caused by platinum-based chemotherapy treatments in children.

Fennec Pharmaceuticals (FRX) Earnings & Revenues

Historic Earnings Reports

FRX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlighted strong revenue growth and market adoption for PEDMARK, supported by strategic expansions and new accounts. However, increased operating expenses and dependency on market expansion present challenges. The momentum in PEDMARK's adoption and international expansion efforts suggest positive future prospects.View all TSE:FRX earnings summaries

FRX Stock 12 Month Forecast

Average Price Target

C$17.91

▲(59.24% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"C$5","18":"C$18","8.25":"C$8.25","11.5":"C$11.5","14.75":"C$14.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17.91465182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$17.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.91465182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$17.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.91465182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$17.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,8.25,11.5,14.75,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.17,11.688819370769231,12.207638741538462,12.726458112307693,13.245277483076922,13.764096853846155,14.282916224615384,14.801735595384615,15.320554966153846,15.839374336923077,16.35819370769231,16.877013078461538,17.39583244923077,{"y":17.91465182,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.17,11.688819370769231,12.207638741538462,12.726458112307693,13.245277483076922,13.764096853846155,14.282916224615384,14.801735595384615,15.320554966153846,15.839374336923077,16.35819370769231,16.877013078461538,17.39583244923077,{"y":17.91465182,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.17,11.688819370769231,12.207638741538462,12.726458112307693,13.245277483076922,13.764096853846155,14.282916224615384,14.801735595384615,15.320554966153846,15.839374336923077,16.35819370769231,16.877013078461538,17.39583244923077,{"y":17.91465182,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.64,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.805,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.21,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >